Pharmacogenetic analysis of adjuvant FOLFOX for Korean patients with colon cancer

Cancer Chemotherapy and Pharmacology

Volumn 71, Issue 4, 2013, Pages 843-851

  Lee, Kyung Hun ^a,b   Chang, Hye Jung ^a   Han, Sae Won ^a,b   Oh, Do Youn ^a,b   Im, Seock Ah ^a,b   Bang, Yung Jue ^a,b,c   Kim, Sun Young ^d   Lee, Keun Wook ^e   Kim, Jee Hyun ^e   Hong, Yong Sang ^f   Kim, Tae Won ^f   Park, Young Suk ^g   Kang, Won Ki ^g   Shin, Sang Joon ^h   Ahn, Joong Bae ^h   Kang, Gyeong Hoon ^b   Jeong, Seung Yong ⁱ   Park, Kyu Joo ⁱ   Park, Jae Gahb ⁱ   Kim, Tae You ^a,b,c  

^a Seoul National University Hospital   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c Seoul National University   (South Korea)

^d National Cancer Center   (South Korea)

^e Seoul National University Bundang Hospital   (South Korea)

^f University of Ulsan College of Medicine   (South Korea)

^g Sungkyunkwan University School of Medicine   (South Korea)

^h Yonsei University College of Medicine   (South Korea)

ⁱ Seoul National University   (South Korea)

Author keywords

Adjuvant chemotherapy; Colon cancer; Oxaliplatin; Polymorphism; Toxicity

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ALANINE GLYOXYLATE AMINOTRANSFERASE; FLUOROURACIL; FOLINIC ACID; GLUTATHIONE TRANSFERASE P1; GLUTATHIONE TRANSFERASE T1; OXALIPLATIN; XERODERMA PIGMENTOSUM GROUP D PROTEIN; ANTINEOPLASTIC AGENT; DNA BINDING PROTEIN; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MTHFR PROTEIN, HUMAN; PLATINUM COMPLEX; X-RAY REPAIR CROSS COMPLEMENTING PROTEIN 1; XRCC1 PROTEIN;

ADENOSINE BINDING CASSETTE TRANSPORTER C2 GENE; ADULT; AGED; ALANINE GLYOXYLATE AMINOTRANSFERASE GENE; ALOPECIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CAUCASIAN; CHEMOTHERAPY INDUCED ANEMIA; CHEMOTHERAPY INDUCED EMESIS; COLON CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG HYPERSENSITIVITY; ETHNIC DIFFERENCE; EXCISION REPAIR CROSS COMPLEMENTING GROUP D GENE; FEBRILE NEUTROPENIA; FEMALE; GENE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; GLUTATHIONE TRANSFERASE P1 GENE; GLUTATHIONE TRANSFERASE T1 GENE; HAND FOOT SYNDROME; HUMAN; MAJOR CLINICAL STUDY; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE GENE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PHARMACOGENETICS; PRIORITY JOURNAL; PROSPECTIVE STUDY; SENSORY NEUROPATHY; SOUTH KOREA; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TS GENE; XERODERMA PIGMENTOSUM GROUP D GENE; ADJUVANT CHEMOTHERAPY; COLON TUMOR; GENETICS; KOREA; MIDDLE AGED; MORTALITY; PROPORTIONAL HAZARDS MODEL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; DNA-BINDING PROTEINS; FEMALE; FLUOROURACIL; GENOTYPE; HUMANS; KOREA; LEUCOVORIN; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROPORTIONAL HAZARDS MODELS;

MLCS; MLOWN;

EID: 84878950045     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-013-2075-3     Document Type: Article

References (31)

1. Allegra CJ, Yothers G, O'Connell MJ, Sharif S, Colangelo LH, Lopa SH, Petrelli NJ, Goldberg RM, Atkins JN, Seay TE, Fehrenbacher L, O'Reilly S, Chu L, Azar CA, Wolmark N (2009) Initial safety report of NSABP C-08: a randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. J Clin Oncol 27:3385-3390
2. Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J (2004) Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350:2343 (Pubitemid 38702845)
3. Boige V, Mendiboure J, Pignon JP, Loriot MA, Castaing M, Barrois M, Malka D, Tregouet DA, Bouche O, Le Corre D, Miran I, Mulot C, Ducreux M, Beaune P, Laurent-Puig P (2010) Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05. J Clin Oncol 28:2556-2564
4. Bosch TM (2008) Pharmacogenomics of drug-metabolizing enzymes and drug transporters in chemotherapy. Methods Mol Biol 448:63-76
5. Chua W, Goldstein D, Lee CK, Dhillon H, Michael M, Mitchell P, Clarke SJ, Iacopetta B (2009) Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer. Br J Cancer 101:998-1004
6. De Gramont A, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, Bonetti A, Clingan P, Lorenzato C, Andre T (2007) Oxaliplatin/5FU/LV in adjuvant colon cancer: updated efficacy results of the MOSAIC trial, including survival, with a median follow-up of six years. J Clin Oncol 25:4007 (Pubitemid 47325605)
7. Edler D, Glimelius B, Hallstrom M, Jakobsen A, Johnston PG, Magnusson I, Ragnhammar P, Blomgren H (2002) Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy. J Clin Oncol 20:1721-1728 (Pubitemid 34273259)
8. Evans WE, McLeod HL (2003) Pharmacogenomics-drug disposition, drug targets, and side effects. N Engl J Med 348:538-549 (Pubitemid 36159890)
9. Fernandez-Contreras ME, Sanchez-Prudencio S, Sanchez-Hernandez JJ, Garcia de Paredes ML, Gisbert JP, Roda-Navarro P, Gamallo C (2006) Thymidylate synthase expression pattern, expression level and single nucleotide polymorphism are predictors for disease-free survival in patients of colorectal cancer treated with 5-fluorouracil. Int J Oncol 28:1303-1310
10. Funke S, Brenner H, Chang-Claude J (2008) Pharmacogenetics in colorectal cancer: a systematic review. Pharmacogenomics 9:1079-1099
11. Gamelin L, Capitain O, Morel A, Dumont A, Traore S, le Anne B, Gilles S, Boisdron-Celle M, Gamelin E (2007) Predictive factors of oxaliplatin neurotoxicity: the involvement of the oxalate outcome pathway. Clin Cancer Res 13:6359-6368 (Pubitemid 350075025)
12. Huang K, Sandler RS, Millikan RC, Schroeder JC, North KE, Hu J (2006) GSTM1 and GSTT1 polymorphisms, cigarette smoking, and risk of colon cancer: a population-based case-control study in North Carolina (United States). Cancer Causes Control 17:385-394
13. Jemal A, Murray T, Ward E, Samuels A, Tiwari R, Ghafoor A, Feuer E, Thun M (2005) Cancer statistics, 2005. CA Cancer J Clin 55:10
14. Kawakami K, Watanabe G (2003) Identification and functional analysis of single nucleotide polymorphism in the tandem repeat sequence of thymidylate synthase gene. Cancer Res 63:6004-6007 (Pubitemid 37187503)
15. Kornmann M, Schwabe W, Sander S, Kron M, Strater J, Polat S, Kettner E, Weiser HF, Baumann W, Schramm H, Hausler P, Ott K, Behnke D, Staib L, Beger HG, Link KH (2003) Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression levels: predictors for survival in colorectal cancer patients receiving adjuvant 5-fluorouracil. Clin Cancer Res 9:4116-4124 (Pubitemid 37204028)
16. Kweekel DM, Gelderblom H, Guchelaar HJ (2005) Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy. Cancer Treat Rev 31:90-105 (Pubitemid 40542888)
17. P-H LEE, Y-S PARK, J-F JI, Y-T FU, Ratanatharathorn V (2009) Safety and tolerability of FOLFOX4 in the adjuvant treatment of colon cancer in Asian patients: the MASCOT study. Asia-Pacific J Clin Oncol 5:101-110
18. Li Y, Gu S, Wu Q, Fu X, Mao Y, Huang Y, Xie Y (2007) No association of ERCC1 C8092A and T19007C polymorphisms to cancer risk: a meta-analysis. Eur J Hum Genet 15:967-973 (Pubitemid 47308473)
19. Little J, Sharp L, Duthie S, Narayanan S (2003) Colon cancer and genetic variation in folate metabolism: the clinical bottom line. J Nutr 133:3758S-3766S (Pubitemid 37392597)
20. Lunn RM, Langlois RG, Hsieh LL, Thompson CL, Bell DA (1999) XRCC1 polymorphisms: effects on aflatoxin B1-DNA adducts and glycophorin A variant frequency. Cancer Res 59:2557-2561 (Pubitemid 29269097)
21. Lurje G, Manegold PC, Ning Y, Pohl A, Zhang W, Lenz HJ (2009) Thymidylate synthase gene variations: predictive and prognostic markers. Mol Cancer Ther 8:1000-1007
22. Lurje G, Zhang W, Yang D, Groshen S, Hendifar AE, Husain H, Nagashima F, Chang HM, Fazzone W, Ladner RD, Pohl A, Ning Y, Iqbal S, El-Khoueiry A, Lenz HJ (2008) Thymidylate synthase haplotype is associated with tumor recurrence in stage II and stage III colon cancer. Pharmacogenet Genomics 18:161-168
23. Morganti M, Ciantelli M, Giglioni B, Putignano AL, Nobili S, Papi L, Landini I, Napoli C, Valanzano R, Cianchi F, Boddi V, Tonelli F, Cortesini C, Mazzei T, Genuardi M, Mini E (2005) Relationships between promoter polymorphisms in the thymidylate synthase gene and mRNA levels in colorectal cancers. Eur J Cancer 41:2176-2183 (Pubitemid 41337961)
24. O'Donnell PH, Dolan ME (2009) Cancer pharmacoethnicity: ethnic differences in susceptibility to the effects of chemotherapy. Clin Cancer Res 15:4806-4814
25. Sanoff HK, Sargent DJ, Green EM, McLeod HL, Goldberg RM (2009) Racial differences in advanced colorectal cancer outcomes and pharmacogenetics: a subgroup analysis of a large randomized clinical trial. J Clin Oncol 27:4109-4115
26. Stoehlmacher J, Park DJ, Zhang W, Groshen S, Tsao-Wei DD, Yu MC, Lenz HJ (2002) Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. J Natl Cancer Inst 94:936-942 (Pubitemid 34778092)
27. van der Put NM, Gabreels F, Stevens EM, Smeitink JA, Trijbels FJ, Eskes TK, van den Heuvel LP, Blom HJ (1998) A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects? Am J Hum Genet 62:1044-1051 (Pubitemid 28199004)
28. Wang D, Lippard SJ (2005) Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 4:307-320 (Pubitemid 41130944)
29. Weisberg I, Tran P, Christensen B, Sibani S, Rozen R (1998) A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab 64:169-172 (Pubitemid 28453294)
30. Won Y, Sung J, Jung K, Kong H, Park S, Shin H, Park E, Ahn Y, Hwang I, Lee D (2009) Nationwide cancer incidence in Korea, 2003-2005. Cancer Res Treat 41:122-131
31. Zhuo X, Cai L, Xiang Z, Li Q, Zhang X (2009) GSTM1 and GSTT1 polymorphisms and nasopharyngeal cancer risk: an evidence-based meta-analysis. J Exp Clin Cancer Res 28:46